Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7484.084 | 1.0151 | 1.0115 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7484.084 | 1.0068 | 1.0052 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7484.084 | 1.0211 | 1.0160 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7484.084 | 0.9745 | 0.9804 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7484.084 | 1.0261 | 1.0197 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7484.084 | 0.8705 | 0.8970 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7484.084 | 0.4195 | 0.4359 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7484.084 | 0.8347 | 0.8668 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7484.084 | 0.0051 | -0.7327 | 2.6217 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7485.085 | 0.9353 | 0.9636 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7485.085 | 0.9724 | 0.9847 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7485.085 | 0.9380 | 0.9651 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7485.085 | 0.9870 | 0.9928 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7485.085 | 0.9753 | 0.9863 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7485.085 | 0.8965 | 0.9408 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7485.085 | 0.8768 | 0.9290 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7485.085 | 0.4481 | 0.6039 | 3.6369 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7485.085 | 1.0920 | 1.0490 | 3.6369 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7487.084 | 1.0052 | 1.0077 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7487.084 | 1.0065 | 1.0097 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7487.084 | 1.0503 | 1.0746 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7487.084 | 1.0324 | 1.0481 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7487.084 | 1.1166 | 1.1717 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7487.084 | 1.1011 | 1.1491 | 1.3396 | |
| MCF 10F | NM | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7487.084 | 0.3783 | -0.0320 | 1.3396 |